CANCER:

Ocular Melanoma

Related cancers:

‹

Melanoma (878)

Uveal Melanoma (83)

Cutaneous Melanoma (76)

Mucosal Melanoma (27)

Melanoma (878)

Uveal Melanoma (83)

Cutaneous Melanoma (76)

Mucosal Melanoma (27)

›

No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	TC Sensitive: A2 - Guideline	TC Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline	ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	temozolomide Sensitive: A2 - Guideline	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: A2 - Guideline	trametinib Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	CaT Sensitive: A2 - Guideline	CaT Sensitive: A2 - Guideline
HLA-A2 positive HLA-A2 positive	Uveal Melanoma Uveal Melanoma	HLA-A2 positive HLA-A2 positive	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: B - Late Trials	IMCgp100 Sensitive: B - Late Trials
HLA-A02:01 positive HLA-A02:01 positive	Uveal Melanoma Uveal Melanoma	HLA-A02:01 positive HLA-A02:01 positive	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: B - Late Trials	IMCgp100 Sensitive: B - Late Trials
BRAF V600 BRAF V600	Ocular Melanoma Ocular Melanoma	BRAF V600 BRAF V600	Ocular Melanoma Ocular Melanoma	vemurafenib Sensitive: C1 - Off-label	vemurafenib Sensitive: C1 - Off-label
BRAF V600 BRAF V600	Ocular Melanoma Ocular Melanoma	BRAF V600 BRAF V600	Ocular Melanoma Ocular Melanoma	trametinib + dabrafenib Sensitive: C1 - Off-label	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Ocular Melanoma Ocular Melanoma	BRAF V600E BRAF V600E	Ocular Melanoma Ocular Melanoma	trametinib + dabrafenib Sensitive: C1 - Off-label	trametinib + dabrafenib Sensitive: C1 - Off-label
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria	selumetinib Sensitive: C2 – Inclusion Criteria
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
MBD4 mutation MBD4 mutation	Uveal Melanoma Uveal Melanoma	MBD4 mutation MBD4 mutation	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
CXCL10 elevation CXCL10 elevation	Uveal Melanoma Uveal Melanoma	CXCL10 elevation CXCL10 elevation	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: C3 – Early Trials	IMCgp100 Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	IDE196 Sensitive: C3 – Early Trials	IDE196 Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials	cabozantinib capsule Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials	AEB071 Sensitive: C3 – Early Trials
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials	AEB071 Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: C3 – Early Trials	ipilimumab Sensitive: C3 – Early Trials
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials	selumetinib Sensitive: C3 – Early Trials
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials	selumetinib Sensitive: C3 – Early Trials
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials	cabozantinib capsule Sensitive: C3 – Early Trials
DDX43 overexpression DDX43 overexpression	Uveal Melanoma Uveal Melanoma	DDX43 overexpression DDX43 overexpression	Uveal Melanoma Uveal Melanoma	selumetinib Resistant: C3 – Early Trials	selumetinib Resistant: C3 – Early Trials
KRAS overexpression KRAS overexpression	Uveal Melanoma Uveal Melanoma	KRAS overexpression KRAS overexpression	Uveal Melanoma Uveal Melanoma	selumetinib Resistant: C3 – Early Trials	selumetinib Resistant: C3 – Early Trials
NRAS overexpression NRAS overexpression	Uveal Melanoma Uveal Melanoma	NRAS overexpression NRAS overexpression	Uveal Melanoma Uveal Melanoma	selumetinib Resistant: C3 – Early Trials	selumetinib Resistant: C3 – Early Trials
PCSK9 underexpression PCSK9 underexpression	Uveal Melanoma Uveal Melanoma	PCSK9 underexpression PCSK9 underexpression	Uveal Melanoma Uveal Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
IL6 elevation IL6 elevation	Uveal Melanoma Uveal Melanoma	IL6 elevation IL6 elevation	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: C3 – Early Trials	IMCgp100 Sensitive: C3 – Early Trials
LDH-L LDH-L	Uveal Melanoma Uveal Melanoma	LDH-L LDH-L	Uveal Melanoma Uveal Melanoma	pembrolizumab + SNDX-275 Sensitive: C3 – Early Trials	pembrolizumab + SNDX-275 Sensitive: C3 – Early Trials
GNAQ G48L + FGFR4 C172G GNAQ G48L + FGFR4 C172G	Uveal Melanoma Uveal Melanoma	GNAQ G48L + FGFR4 C172G GNAQ G48L + FGFR4 C172G	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: C4 – Case Studies	trametinib Sensitive: C4 – Case Studies
MBD4 mutation MBD4 mutation	Uveal Melanoma Uveal Melanoma	MBD4 mutation MBD4 mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
MBD4 L563T MBD4 L563T	Uveal Melanoma Uveal Melanoma	MBD4 L563T MBD4 L563T	Uveal Melanoma Uveal Melanoma	pembrolizumab + ipilimumab Sensitive: C4 – Case Studies	pembrolizumab + ipilimumab Sensitive: C4 – Case Studies
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	TAK-733 Sensitive: D – Preclinical	TAK-733 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	TAK-733 Sensitive: D – Preclinical	TAK-733 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	enzastaurin Sensitive: D – Preclinical	enzastaurin Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	enzastaurin Sensitive: D – Preclinical	enzastaurin Sensitive: D – Preclinical
GNRH1 expression GNRH1 expression	Uveal Melanoma Uveal Melanoma	GNRH1 expression GNRH1 expression	Uveal Melanoma Uveal Melanoma	zoptarelin doxorubicin Sensitive: D – Preclinical	zoptarelin doxorubicin Sensitive: D – Preclinical
CDK9 overexpression CDK9 overexpression	Uveal Melanoma Uveal Melanoma	CDK9 overexpression CDK9 overexpression	Uveal Melanoma Uveal Melanoma	SNS-032 Sensitive: D – Preclinical	SNS-032 Sensitive: D – Preclinical
CDK7 overexpression CDK7 overexpression	Uveal Melanoma Uveal Melanoma	CDK7 overexpression CDK7 overexpression	Uveal Melanoma Uveal Melanoma	SNS-032 Sensitive: D – Preclinical	SNS-032 Sensitive: D – Preclinical
BAP1 mutation BAP1 mutation	Uveal Melanoma Uveal Melanoma	BAP1 mutation BAP1 mutation	Uveal Melanoma Uveal Melanoma	JNJ 26481585 Sensitive: D – Preclinical	JNJ 26481585 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: D – Preclinical	AEB071 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical	trametinib + GSK2126458 Sensitive: D – Preclinical
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical	trametinib + GSK2126458 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	selumetinib + AZD8055 Sensitive: D – Preclinical	selumetinib + AZD8055 Sensitive: D – Preclinical
BRAF V600E BRAF V600E	Uveal Melanoma Uveal Melanoma	BRAF V600E BRAF V600E	Uveal Melanoma Uveal Melanoma	selumetinib + AZD8055 Sensitive: D – Preclinical	selumetinib + AZD8055 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	selumetinib + AZD8055 Sensitive: D – Preclinical	selumetinib + AZD8055 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical	AEB071 + AHT956 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical	AEB071 + AHT956 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	TAK-733 Sensitive: D – Preclinical	TAK-733 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical	trametinib + GSK2126458 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	Tris DBA Sensitive: D – Preclinical	Tris DBA Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	FR900359 Sensitive: D – Preclinical	FR900359 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	FR900359 Sensitive: D – Preclinical	FR900359 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	U0126 Sensitive: D – Preclinical	U0126 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: D – Preclinical	selumetinib Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: D – Preclinical	AEB071 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: D – Preclinical	trametinib Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical	binimetinib + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical	AEB071 + CGM097 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical	binimetinib + AEB071 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	verteporfin Sensitive: D – Preclinical	verteporfin Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical	everolimus + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical	binimetinib + AEB071 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical	AEB071 + CGM097 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical	everolimus + AEB071 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	FR900359 Sensitive: D – Preclinical	FR900359 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	JQ-1 Sensitive: D – Preclinical	JQ-1 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	JQ-1 Sensitive: D – Preclinical	JQ-1 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical	PD-0325901 + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical	PD-0325901 + AEB071 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical	trametinib + hydroxychloroquine Sensitive: D – Preclinical
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical	trametinib + hydroxychloroquine Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical	trametinib + hydroxychloroquine Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical	MEK inhibitor + YM-254890 Sensitive: D – Preclinical
CYSLTR2 L129Q CYSLTR2 L129Q	Uveal Melanoma Uveal Melanoma	CYSLTR2 L129Q CYSLTR2 L129Q	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical	MEK inhibitor + YM-254890 Sensitive: D – Preclinical
GNAQ R183Q GNAQ R183Q	Uveal Melanoma Uveal Melanoma	GNAQ R183Q GNAQ R183Q	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical	MEK inhibitor + YM-254890 Sensitive: D – Preclinical
GNAQ G48V GNAQ G48V	Uveal Melanoma Uveal Melanoma	GNAQ G48V GNAQ G48V	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical	MEK inhibitor + YM-254890 Sensitive: D – Preclinical

Ocular Melanoma

Associations(86)

Associations
(86)